] . 2019. “Safety And Efficacy Of Vrc01 Broadly Neutralising Antibodies In Adults With Acutely Treated Hiv (Rv397): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial.”. Lancet Hiv 6 (5). Lancet Hiv: e297-e306. doi:10.1016/S2352-3018(19)30053-0.
. 2012. “The Thai Phase Iii Trial (Rv144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes Within The V2 Region Of Hiv-1 Envelope.”. J Immunol 188 (10). J Immunol: 5166-76. doi:10.4049/jimmunol.1102756.